- Home
- GLQ vs PLX Comparison
GLQ vs PLX Comparison
Compare GLQ & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- PLX
- Stock Information
- Founded
- GLQ 2005
- PLX 1993
- Country
- GLQ United States
- PLX United States
- Employees
- GLQ N/A
- PLX N/A
- Industry
- GLQ Finance/Investors Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLQ Finance
- PLX Health Care
- Exchange
- GLQ Nasdaq
- PLX Nasdaq
- Market Cap
- GLQ 142.0M
- PLX 164.2M
- IPO Year
- GLQ N/A
- PLX 1998
- Fundamental
- Price
- GLQ $7.67
- PLX $2.56
- Analyst Decision
- GLQ
- PLX Strong Buy
- Analyst Count
- GLQ 0
- PLX 1
- Target Price
- GLQ N/A
- PLX $15.00
- AVG Volume (30 Days)
- GLQ 65.5K
- PLX 809.2K
- Earning Date
- GLQ 01-01-0001
- PLX 11-13-2025
- Dividend Yield
- GLQ 11.11%
- PLX N/A
- EPS Growth
- GLQ N/A
- PLX N/A
- EPS
- GLQ N/A
- PLX 0.08
- Revenue
- GLQ N/A
- PLX $61,948,000.00
- Revenue This Year
- GLQ N/A
- PLX $14.53
- Revenue Next Year
- GLQ N/A
- PLX $75.77
- P/E Ratio
- GLQ N/A
- PLX $31.38
- Revenue Growth
- GLQ N/A
- PLX 62.79
- 52 Week Low
- GLQ $5.13
- PLX $0.99
- 52 Week High
- GLQ $6.54
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- GLQ 64.88
- PLX 81.38
- Support Level
- GLQ $7.56
- PLX $1.52
- Resistance Level
- GLQ $7.58
- PLX $2.12
- Average True Range (ATR)
- GLQ 0.07
- PLX 0.11
- MACD
- GLQ -0.00
- PLX 0.05
- Stochastic Oscillator
- GLQ 72.65
- PLX 97.88
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.